Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
10,824
result(s) for
"Wu, Chi"
Sort by:
Agile innovation : the revolutionary approach to accelerate success, inspire engagement, and ignite creativity
\"Effective innovation doesn't happen by accident - it happens by design! Agile Innovation is the field guide to designing and implementing effective innovation methods and projects, and facilitating collaborative processes that enable people to solve complex problems and create breakthrough solutions. The book offers a comprehensive Innovation Master Plan Framework, which provides five critical performance areas and how to optimize them for sustained innovation improvement. Agile Innovation teaches how to discover and develop better ideas, learn and work together more profitably and effectively, and create breakthroughs\"-- Provided by publisher.
Book
The role of host–guest interactions in organic emitters employing MR-TADF
Research into organic light emitters employing multiple resonance-induced thermally activated delayed fluorescence (MR-TADF) materials is presently attracting a great deal of attention due to the potential for efficient deep-blue emission. However, the origins and mechanisms of successful TADF are unclear, as many MR-TADF materials do not show TADF behaviour in solution, but only as particular pure solids. Here, an investigation into a well-known MR-TADF material, DABNA-1, together with other new MR materials (9H-quinolino[3,2,1-kl]phenothiazin-9-one (QPO) and 9H-quinolino-[3,2,1-kl]-phenothiazin-9-one 5,5-dioxide (QP3O)), yields new insights regarding the origin of TADF. Although a material system may support the concept of MR, inefficiency in both forward and reverse intersystem crossings forbids TADF unless a suitable host material allows an exciplex-like host–emitter interaction that boosts TADF. This boosted-TADF mechanism can be generalized to any fluorescence dye that lacks TADF in the photoluminescence measurement but has a thermally accessible S1–T1 energy gap, opening the way to high-performance organic light-emitting diodes.This study reveals the importance of host–guest interactions for effective multiple-resonance thermally activated delayed fluorescence in organic light emitters.
Journal Article
سرقة فاكهة الجينسنغ
في بداية العالم عم الظلام الكون في الفترة التي سميت بـ «الفوضى الأزلية». وبعد مرور 5400 عام، طارت المواد الخفيفة إلى السماء وتحولت إلى الشمس والقمر والنجوم والأجرام الفلكية، وبعد 5400 عام أخرى تجمدت المواد الثقيلة وكونت المياه والنار والجبال والصخور والتربة، وبمرور 5400 عام أخرى وجدت الحياة على الأرض وانقسم العالم إلى أربع قارات الشرقية والغربية والجنوبية والشمالية، وفي القارة الشرقية كان هناك جبل يسمى جبل الأزهار والثمار على قمته صخرة خالدة، تعرضت الصخرة لضوء الشمس والقمر فاكتسبت قدرات خارقة، إلى أن انفجرت وجلبت الفوضى للعالم. وبعد أكثر من 500 كلف راهب من القارة الجنوبية بإحضار الكتب المقدسة من القارة عام الغربية للقضاء على الكوارث والآلام في العالم، ولم تنجح رحلته إلا بعد أن مر بعقبات بلغ عددها 81 عقبة. وترتبط هذه الأسطورة ارتباطا وثيقا بشخصية «القرد» الذي تجرأ وأعلن تمرده على السماء والأرض.
Book
Development of revised ResNet-50 for diabetic retinopathy detection
Background
Diabetic retinopathy (DR) produces bleeding, exudation, and new blood vessel formation conditions. DR can damage the retinal blood vessels and cause vision loss or even blindness. If DR is detected early, ophthalmologists can use lasers to create tiny burns around the retinal tears to inhibit bleeding and prevent the formation of new blood vessels, in order to prevent deterioration of the disease. The rapid improvement of deep learning has made image recognition an effective technology; it can avoid misjudgments caused by different doctors’ evaluations and help doctors to predict the condition quickly. The aim of this paper is to adopt visualization and preprocessing in the ResNet-50 model to improve module calibration, to enable the model to predict DR accurately.
Results
This study compared the performance of the proposed method with other common CNNs models (Xception, AlexNet, VggNet-s, VggNet-16 and ResNet-50). In examining said models, the results alluded to an over-fitting phenomenon, and the outcome of the work demonstrates that the performance of the revised ResNet-50 (Train accuracy: 0.8395 and Test accuracy: 0.7432) is better than other common CNNs (that is, the revised structure of ResNet-50 could avoid the overfitting problem, decease the loss value, and reduce the fluctuation problem).
Conclusions
This study proposed two approaches to designing the DR grading system: a standard operation procedure (SOP) for preprocessing the fundus image, and a revised structure of ResNet-50, including an adaptive learning rating to adjust the weight of layers, regularization and change the structure of ResNet-50, which was selected for its suitable features. It is worth noting that the purpose of this study was not to design the most accurate DR screening network, but to demonstrate the effect of the SOP of DR and the visualization of the revised ResNet-50 model. The results provided an insight to revise the structure of CNNs using the visualization tool.
Journal Article
The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative Stress-Related Eye Diseases
Oxidative stress is an important pathomechanism found in numerous ocular degenerative diseases. To provide a better understanding of the mechanism and treatment of oxidant/antioxidant imbalance-induced ocular diseases, this article summarizes and provides updates on the relevant research. We review the oxidative damage (e.g., lipid peroxidation, DNA lesions, autophagy, and apoptosis) that occurs in different areas of the eye (e.g., cornea, anterior chamber, lens, retina, and optic nerve). We then introduce the antioxidant mechanisms present in the eye, as well as the ocular diseases that occur as a result of antioxidant imbalances (e.g., keratoconus, cataracts, age-related macular degeneration, and glaucoma), the relevant antioxidant biomarkers, and the potential of predictive diagnostics. Finally, we discuss natural antioxidant therapies for oxidative stress-related ocular diseases.
Journal Article
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines
The coronavirus disease 2019 (COVID-19) pandemic caused by a novel coronavirus, SARS-CoV-2, has infected more than 22 million individuals and resulted in over 780,000 deaths globally. The rapid spread of the virus and the precipitously increasing numbers of cases necessitate the urgent development of accurate diagnostic methods, effective treatments, and vaccines. Here, we review the progress of developing diagnostic methods, therapies, and vaccines for SARS-CoV-2 with a focus on current clinical trials and their challenges. For diagnosis, nucleic acid amplification tests remain the mainstay diagnostics for laboratory confirmation of SARS-CoV-2 infection, while serological antibody tests are used to aid contact tracing, epidemiological, and vaccine evaluation studies. Viral isolation is not recommended for routine diagnostic procedures due to safety concerns. Currently, no single effective drug or specific vaccine is available against SARS-CoV-2. Some candidate drugs targeting different levels and stages of human responses against COVID-19 such as cell membrane fusion, RNA-dependent RNA polymerase, viral protease inhibitor, interleukin 6 blocker, and convalescent plasma may improve the clinical outcomes of critical COVID-19 patients. Other supportive care measures for critical patients are still necessary. Advances in genetic sequencing and other technological developments have sped up the establishment of a variety of vaccine platforms. Accordingly, numerous vaccines are under development. Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity, and most of these candidates have recently moved into clinical trials. Before the efficacy of such vaccines in humans is demonstrated, strong international coordination and collaboration among studies, pharmaceutical companies, regulators, and governments are needed to limit further damage due the emerging SARS-CoV-2 virus.
Journal Article
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
BackgroundImmune checkpoint inhibitors (ICIs) are promising agents for unresectable hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut microbiome can modulate tumor response to immunotherapy, but its effect on HCC remains unclear.MethodsFrom May 2018 to February 2020, patients receiving ICI treatment for uHCC were prospectively enrolled; their fecal samples were collected before treatment. The fecal microbiota and metabolites were analyzed from 20 patients with radiology-proven objective responses (OR) and 21 randomly selected patients with progressive disease (PD). After March 2020, 33 consecutive Child-Pugh-A patients were recruited as a validation cohort. Additionally, feces from 17 healthy volunteers were collected for comparison of background microbes.ResultsA significant dissimilarity was observed in fecal bacteria between patients with OR and patients with PD before immunotherapy. Prevotella 9 was enriched in patients with PD, whereas Lachnoclostridium, Lachnospiraceae, and Veillonella were predominant in patients with OR. Ursodeoxycholic acid and ursocholic acid were significantly enriched in the feces of patients with OR and strongly correlated with the abundance of Lachnoclostridium. The coexistence of Lachnoclostridium enrichment and Prevotella 9 depletion significantly predicted better overall survival (OS). In the validation cohort, better progression-free survival (PFS) and OS were noted in patients who had a preferable microbial signature in comparison with counter-group (PFS: 8.8 months vs 1.8 months; OS: not reached vs 6.5 months, both p<0.001).ConclusionsFecal microbiota and bile acids were associated with outcomes of immunotherapy for uHCC. These findings highlight the potential role of gut microbiota and metabolites as biomarkers to predict outcomes of ICI-treated HCC.
Journal Article
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
Journal Article